Indapta Therapeutics, Inc., a privately held clinical stage biotechnology company developing next-generation differentiated immunotherapies for the treatment of cancer and autoimmune diseases, today ...

Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 ...

Hangzhou Qihan Biotech Co., Ltd. (“Qihan” or “Qihan Biotech” or “the Company”), an industry leader in applying multiplexable genome editing technology to cell therapies and organ transplantation, ...

Nkarta, Inc. (($NKTX)) announced an update on their ongoing clinical study. Study Overview: Nkarta, Inc. is conducting a Phase 1 study titled ‘A ...

Modifications to a type of immune cell programmed to recognize and kill cancerous tumors could make them even more effective ...

Dr. Song’s presentation will detail how enhanced natural killer cells can maximize the body’s ability to destroy diseased and abnormal cells and provide a review of NK cell therapy as an alternative ...

Artiva Biotherapeutics, Inc. (($ARTV)) announced an update on their ongoing clinical study. Artiva Biotherapeutics, Inc. is conducting a Phase 2a ...

A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates ...

CD19 CAR NK cell therapy, alone or with rituximab, shows promise in relapsed/refractory B-cell NHL, including Waldenström macroglobulinemia. Two heavily pretreated WM patients achieved complete ...

GC Cell announced on the 31st that its HER2-targeted allogeneic CAR-NK cell therapy, 'AB-201 (GCC2003),' has received simultaneous approvals for its ...

Ianalumab targets the B-cell activating factor receptor (BAFR) and ibrutinib belongs to a class of therapeutics called Bruton ...

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately ...